RESEARCH TRIANGLE PARK, N.C., June 18, 2014 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq: SCYX ) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' President and Chief Executive Officer, will present at the 9 th Annual JMP Securities Healthcare Conference at the Westin Grand Central Hotel in New York City on Tuesday, June 24, 2014, at 3:00 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com . A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com .
Company Chuck Osborne Chief Financial Officer Tel: 919-544-8600 E-mail: Investor/Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 E-mail: